KMT2D

Across TCGA pan-cancer cohorts, KMT2D Mutation is linked to patient survival in 13 of 34 cancer types, making it a survival-associated KMT2D data layer compared with 19 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher KMT2D Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KMT2D expression acts as an unfavorable survival marker, although some lineages such as BLCA and STAD show a favorable association.

UCS, LUSC, and COAD are the cancer types where KMT2D Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	DFS	Median	II,III,IV	0.119	0.478	.002	18	view →
LUSC	DFS	Median	II,III,IV	0.416	0.772	.011	15	view →
COAD	OS	Median	IV	0.174	0.684	<.001	12	view →
BLCA	OS	Median	All	0.794	0.343	.023	12	view →
READ	DFS	Median	All	0.182	0.798	.010	9	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	9	view →
THCA	DFS	Median	All	0.133	0.842	.001	6	view →
DLBC	OS	Median	III,IV	0.172	1.000	.014	6	view →
ESCA	OS	Median	III,IV	0.266	0.586	.026	6	view →
LIHC	OS	Median	All	0.444	0.778	.010	6	view →
STAD	OS	Median	III,IV	0.802	0.350	.008	5	view →
PRAD	DFS	Median	All	0.726	0.936	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

KMT2D–UCS (DFS)

Open the UCS breakdown →